It's Time to Re-Examine the Diagnostics Opportunity
This article was originally published in Start Up
Executive Summary
Investments in in vitro diagnostics companies have long been shunned by venture capital investors. But with biotherapeutic companies increasingly unremunerative, VCs are looking to put advances in the new biology to use in diagnostics--and they're seeing some success stories to justify their investments.